Relevant bibliographies by topics / T2 MRI-guided

Academic literature on the topic 'T2 MRI-guided'

Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'T2 MRI-guided.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "T2 MRI-guided"

1

Freedman, Joshua N., David J. Collins, Oliver J. Gurney-Champion, Jamie R. McClelland, Simeon Nill, Uwe Oelfke, Martin O. Leach, and Andreas Wetscherek. "Super-resolution T2-weighted 4D MRI for image guided radiotherapy." Radiotherapy and Oncology 129, no. 3 (December 2018): 486–93. http://dx.doi.org/10.1016/j.radonc.2018.05.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dooley, Sarah, Ricardo LLorente, Kolton Jones, John Ford, and Eric Mellon. "RTHP-22. EDEMA PROGRESSION DURING MRI-GUIDED GLIOBLASTOMA RADIOTHERAPY." Neuro-Oncology 21, Supplement_6 (November 2019): vi214. http://dx.doi.org/10.1093/neuonc/noz175.893.

Full text
Abstract:
Abstract PURPOSE Despite the common finding of pseudoprogression or true progression one month after primary chemoradiotherapy for glioblastoma, there are few studies evaluating brain MRI changes that occur during concurrent chemotherapy and radiotherapy (RT). With the first generation combination MRI-RT device, daily predominantly T2-weighted MRIs are obtained of glioblastoma during RT. We quantified how many patients had significant MRI detectable volumetric changes through the six week course of primary chemoradiotherapy. This is of particular importance since glioblastoma RT is only planned at the beginning of therapy and not commonly re-planned for changes during therapy. METHODS We retrospectively reviewed the daily set-up imaging of 8 patients at our institution who received RT for glioblastoma using the Cobalt-60 MRI-RT system. Patients received standard chemoradiation at 60 Gy in 30 fractions with temozolomide per EORTC22981/26981. We contoured the abnormality on the initial ViewRay setup scan and the set-up scan for fraction 30. After rigid fusion of the contours of the initial setup MRI and fraction 30 MRI, the volumes were compared. RESULTS Of the 8 patients, 3 patients (37.5%) demonstrated edema expansion greater than 5 mm. The maximum distances of T2-weighted abnormality volume growth for these patients were 1.0 cm, 1.5 cm, and 4.1 cm. These findings were correlated with the post-treatment diagnostic MRIs at 3–4 weeks which demonstrated similar FLAIR abnormalities and expansion in T1 with gadolinium contrast volumes within these areas of the radiotherapy fields (pseudoprogression vs. true progression). CONCLUSION Review of MRIs obtained by daily MRI-RT for glioblastoma indicates that 3 of 8 patients had over 5 mm of change in T2-weighted dimensions from beginning to end of radiotherapy. Groups using limited CTV margins for treatment planning should be aware that MRI volumes could significantly increase during radiotherapy.
APA, Harvard, Vancouver, ISO, and other styles
3

Lu, Yu, Peng Zhang, Lihao Lin, Xuan Gao, Yifei Zhou, Jing Feng, and Hongjie Zhang. "Ultra-small bimetallic phosphides for dual-modal MRI imaging guided photothermal ablation of tumors." Dalton Transactions 51, no. 11 (2022): 4423–28. http://dx.doi.org/10.1039/d1dt03898b.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhao, Ying, Yang Liu, Yinghui Wang, Bo Xu, Songtao Zhang, Jianhua Liu, Tianqi Zhang, Longhai Jin, Shuyan Song, and Hongjie Zhang. "Correction: Rapidly clearable MnCo2O4@PAA as novel nanotheranostic agents for T1/T2 bimodal MRI imaging-guided photothermal therapy." Nanoscale 13, no. 48 (2021): 20703. http://dx.doi.org/10.1039/d1nr90222a.

Full text
Abstract:
Correction for ‘Rapidly clearable MnCo2O4@PAA as novel nanotheranostic agents for T1/T2 bimodal MRI imaging-guided photothermal therapy’ by Ying Zhao et al., Nanoscale, 2021, 13, 16251–16257, DOI: 10.1039/D1NR04067G.
APA, Harvard, Vancouver, ISO, and other styles
5

Zhang, Hao, Yaodong Chen, Yunyu Cai, Jun Liu, Pengfei Liu, Zizhuo Li, Tingting An, Xiuhua Yang, and Changhao Liang. "Paramagnetic CuS hollow nanoflowers for T2-FLAIR magnetic resonance imaging-guided thermochemotherapy of cancer." Biomaterials Science 7, no. 1 (2019): 409–18. http://dx.doi.org/10.1039/c8bm01412d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Valles, Francisco, Massimo S. Fiandaca, Jamie L. Eberling, Philip A. Starr, Paul S. Larson, Chadwick W. Christine, John Forsayeth, et al. "Qualitative Imaging of Adeno-Associated Virus Serotype 2–Human Aromatic L-Amino Acid Decarboxylase Gene Therapy in a Phase I Study for the Treatment of Parkinson Disease." Neurosurgery 67, no. 5 (November 1, 2010): 1377–85. http://dx.doi.org/10.1227/neu.0b013e3181f53a5c.

Full text
Abstract:
Abstract BACKGROUND: Putaminal convection-enhanced delivery (CED) of an adeno-associated virus serotype 2 (AAV2) vector, containing the human aromatic L-amino acid decarboxylase (hAADC) gene for the treatment of Parkinson disease (PD), has completed a phase I clinical trial. OBJECTIVE: To retrospectively analyze magnetic resonance imaging (MRI) and positron emission tomography (PET) data from the phase I trial, correlate those data with similar nonhuman primate (NHP) data, and present how such information may improve future PD gene therapy trials in preparation for the initiation of the phase II trial. METHODS: Ten patients with PD had been treated with bilateral MRI-guided putaminal infusions of AAV2-hAADC. MRI and PET scans were obtained at baseline (before vector administration) and at various intervals after treatment. Three normal adult NHPs received similar infusions into the thalamus. Imaging studies for both groups are presented, as well as hAADC immunohistochemistry for the NHPs. RESULTS: Early post-CED MRI confirmed the stereotactic targeting accuracy and revealed T2 hyperintensity around the distal cannula tracts, best seen within 4 hours of surgery. Coregistration of post-CED MRI and PET scans revealed increased PET uptake at the sites of T2 hyperintensity. Similar T2 hyperintensities in NHP MRI correlated with hAADC immunohistochemistry. CONCLUSION: Our analysis confirms the correct targeting of the CED cannula tracts within the target human putamen. Coregistration of MRI and PET confirms colocalization of T2 hyperintensities and increased PET uptake around the distal cannula tracts. Because PET uptake closely correlates with hAADC transgene expression and NHP data confirm this relationship between T2 hyperintensity and hAADC immunohistochemistry, we believe that T2-weighted MRI allows visualization of a significant part of the distribution volume of the hAADC gene therapy. Recommendations for future protocols based on these data are presented.
APA, Harvard, Vancouver, ISO, and other styles
7

Lu, Wei, Yuxuan Liao, Chunzhu Jiang, Ruoming Wang, Xueru Shan, Qian Chen, Guoying Sun, and Jianhua Liu. "Polydopamine-coated NaGdF4:Dy for T1/T2-weighted MRI/CT multimodal imaging-guided photothermal therapy." New Journal of Chemistry 43, no. 19 (2019): 7371–78. http://dx.doi.org/10.1039/c9nj00561g.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cho, Hyung Ji, Sung Hun Kim, Bong Joo Kang, Hanna Kim, Byung Joo Song, and Ah Won Lee. "Leiomyoma of the nipple diagnosed by MRI." Acta Radiologica Short Reports 1, no. 9 (October 2012): 1–4. http://dx.doi.org/10.1258/arsr.2012.120025.

Full text
Abstract:
Leiomyoma of the nipple is a rare, benign, non-epithelial tumor that is thought to arise from smooth muscle fibers in the subareolar tissue of the breast. We report an unusual case of leiomyoma of the nipple in a 32-year-old woman in whom the diagnosis was made by ultrasound-guided core needle biopsy. She came to our hospital complaining of a recently enlarged nipple with discharge and erosion in the region of the left nipple-areolar complex. This mass was evaluated by mammography, ultrasonography, and magnetic resonance imaging (MRI). To the best of our knowledge, this is the first case of a leiomyoma of the nipple examined by MRI. MRI showed an oval mass with circumscribed margins that appeared as an intermediate signal intensity on both T1- and T2-weighted images. A dynamic MRI study showed a rim-enhancing oval mass with delayed persistent enhancement. Ultrasound-guided core needle biopsy revealed spindle cell proliferation consistent with leiomyoma of the nipple.
APA, Harvard, Vancouver, ISO, and other styles
9

Tamura, Ryo, Katsunori Kashima, Mina Asatani, Koji Nishino, Nobumichi Nishikawa, Masayuki Sekine, Takehiro Serikawa, and Takayuki Enomoto. "Preoperative Ultrasound-Guided Needle Biopsy of 63 Uterine Tumors Having High Signal Intensity Upon T2-Weighted Magnetic Resonance Imaging." International Journal of Gynecologic Cancer 24, no. 6 (July 2014): 1042–47. http://dx.doi.org/10.1097/igc.0000000000000189.

Full text
Abstract:
ObjectiveThe differential diagnosis between uterine sarcoma and benign leiomyoma is difficult when made only by magnetic resonance imaging (MRI); it usually requires an additional preoperative diagnostic procedure. We report our results using ultrasound-guided needle biopsy for these types of uterine tumors.MethodsUltrasound-guided needle biopsy was performed on 63 patients with uterine smooth muscle tumors suspected of malignancy by MRI. We compared the results of presurgical biopsy against the postsurgical pathology of the tumor.ResultsAmong 63 patients with a high signal intensity of the uterine tumor on T2-weighted MRI (1 case was undetermined), 12 cases (19.3%) were diagnosed by the needle biopsy as malignant, and 51 cases (80.6%) were benign. Among the 12 diagnosed as malignant tumors, 11 had surgery performed, and one was treated with chemotherapy. Among the 51 patients diagnosed with a benign tumor, 27 had surgery performed, and 24 were put on a wait-and-see clinical follow-up schedule. One of the 27 surgical patients with a benign tumor had a postsurgical diagnosis of a low-grade endometrial stromal sarcoma. In the 38 cases where surgery was performed, we found the sensitivity, specificity, and the positive and negative predictive values of the needle biopsy were 91.7%, 100%, 100%, and 96.2%, respectively.ConclusionsUltrasound-guided needle biopsy may be a reliable preoperative diagnostic procedure for uterine tumors with suspected malignancy.
APA, Harvard, Vancouver, ISO, and other styles
10

Luo, Shun, Shuijie Qin, Gerile Oudeng, and Li Zhang. "Iron-Based Hollow Nanoplatforms for Cancer Imaging and Theranostics." Nanomaterials 12, no. 17 (August 31, 2022): 3023. http://dx.doi.org/10.3390/nano12173023.

Full text
Abstract:
Over the past decade, iron (Fe)-based hollow nanoplatforms (Fe-HNPs) have attracted increasing attention for cancer theranostics, due to their high safety and superior diagnostic/therapeutic features. Specifically, Fe-involved components can serve as magnetic resonance imaging (MRI) contrast agents (CAs) and Fenton-like/photothermal/magnetic hyperthermia (MTH) therapy agents, while the cavities are able to load various small molecules (e.g., fluorescent dyes, chemotherapeutic drugs, photosensitizers, etc.) to allow multifunctional all-in-one theranostics. In this review, the recent advances of Fe-HNPs for cancer imaging and treatment are summarized. Firstly, the use of Fe-HNPs in single T1-weighted MRI and T2-weighted MRI, T1-/T2-weighted dual-modal MRI as well as other dual-modal imaging modalities are presented. Secondly, diverse Fe-HNPs, including hollow iron oxide (IO) nanoparticles (NPs), hollow matrix-supported IO NPs, hollow Fe-complex NPs and hollow Prussian blue (PB) NPs are described for MRI-guided therapies. Lastly, the potential clinical obstacles and implications for future research of these hollow Fe-based nanotheranostics are discussed.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "T2 MRI-guided"

1

Lee, Christine U., and James F. Glockner. "Case 12.19." In Mayo Clinic Body MRI Case Review, edited by Christine U. Lee and James F. Glockner, 601–2. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199915705.003.0317.

Full text
Abstract:
62-year-old man with a history of prostate carcinoma (Gleason score 3+3) on ultrasound-guided biopsy Axial T2-weighted FRFSE images (Figure 12.19.1) obtained with an endorectal coil demonstrate a hypointense lesion in the left anterior peripheral zone with probable involvement of the central gland. The lesion shows high signal intensity on axial diffusion-weighted images (b=1,000 s/mm...
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "T2 MRI-guided"

1

Nanda, Siddhartha, Jacob T. Antunes, Amrish Selvam, Kaustav Bera, Justin T. Brady, Jayakrishna Gollamudi, Kenneth Friedman, et al. "Integrating radiomic features from T2-weighted and contrast-enhanced MRI to evaluate pathologic rectal tumor regression after chemoradiation." In Image-Guided Procedures, Robotic Interventions, and Modeling, edited by Baowei Fei and Cristian A. Linte. SPIE, 2019. http://dx.doi.org/10.1117/12.2513945.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'T2 MRI-guided' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography